Provided by Tiger Trade Technology Pte. Ltd.

Tectonic Therapeutic, Inc.

24.83
+0.46001.89%
Pre-market: 17.95-6.8800-27.71%04:10 EST
Volume:266.74K
Turnover:6.55M
Market Cap:464.73M
PE:-6.40
High:25.00
Open:24.42
Low:23.67
Close:24.37
52wk High:36.11
52wk Low:13.70
Shares:18.72M
Float Shares:9.74M
Volume Ratio:0.58
T/O Rate:2.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8785
EPS(LYR):-6.8293
ROE:-32.21%
ROA:-21.46%
PB:1.74
PE(LYR):-3.64

Loading ...

Tectonic Therapeutic (TECX) Initiated with a Buy at LifeSci Capital

TIPRANKS
·
Feb 08

Tectonic Therapeutic Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 09

Tectonic Therapeutic to Participate in Investor Conferences

Reuters
·
Dec 01, 2025

Mizuho Securities Reaffirms Their Buy Rating on Tectonic Therapeutic (TECX)

TIPRANKS
·
Nov 20, 2025

Tectonic Therapeutic Q3 EPS $(1.02) Beats $(1.05) Estimate

Benzinga
·
Nov 07, 2025

Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights

THOMSON REUTERS
·
Nov 07, 2025

Tectonic Therapeutic Shares Rise in Premarket on Positive Data for XT45 Drug

Dow Jones
·
Oct 30, 2025

Mizuho Securities Keeps Their Buy Rating on Tectonic Therapeutic (TECX)

TIPRANKS
·
Oct 30, 2025

Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients

Reuters
·
Oct 30, 2025

Tectonic Therapeutic Inc - Tx45 Well Tolerated With No Serious Adverse Events in Ph-Hfref

THOMSON REUTERS
·
Oct 30, 2025

Tectonic Therapeutic Inc - Tx45 Improves Heart Function and Pulmonary Hemodynamics in Ph-Hfref

THOMSON REUTERS
·
Oct 30, 2025

Tectonic Therapeutic Announces Positive Topline Data From Phase 1B Part B Clinical Trial for Tx45 in Patients With Group 2 Pulmonary Hypertension in Hfref

THOMSON REUTERS
·
Oct 30, 2025

Mizuho Securities Sticks to Their Buy Rating for Tectonic Therapeutic (TECX)

TIPRANKS
·
Oct 22, 2025

Mizuho Securities Keeps Their Buy Rating on Tectonic Therapeutic (TECX)

TIPRANKS
·
Oct 14, 2025

Tectonic Therapeutic Shares up 4.4% Premarket After Oppenheimer Initiates Coverage With Outperform Rating

THOMSON REUTERS
·
Sep 03, 2025

Oppenheimer Initiates Tectonic Therapeutic at Outperform With $80 Price Target

MT Newswires Live
·
Sep 03, 2025

Top Premarket Decliners

MT Newswires Live
·
Sep 02, 2025

Tectonic Therapeutic Inc. to Participate in Upcoming September Investor Conferences

Reuters
·
Aug 28, 2025

TScan Therapeutics Appoints Leiden Dworak as Principal Accounting Officer, Jason Amello Continues as CFO

Reuters
·
Aug 21, 2025